$502 Million is the total value of Paradigm Biocapital Advisors LP's 23 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 48.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $53,823,000 | +78.1% | 978,596 | +17.7% | 10.73% | +34.3% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $46,186,000 | +37.9% | 1,445,566 | +49.5% | 9.21% | +4.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $44,304,000 | +447.7% | 659,968 | +570.8% | 8.83% | +313.0% |
| SRRA | Buy | SIERRA ONCOLOGY INC | $44,064,000 | +78.2% | 801,314 | +3.9% | 8.79% | +34.4% |
| INCY | Buy | INCYTE CORP | $42,243,000 | +126.9% | 556,043 | +137.2% | 8.42% | +71.1% |
| ASND | Buy | ASCENDIS PHARMA A/Ssponsored adr | $40,175,000 | +6.4% | 432,170 | +34.4% | 8.01% | -19.7% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $38,425,000 | +183.2% | 163,066 | +115.6% | 7.66% | +113.5% |
| ARGX | New | ARGENX SEsponsored adr | $33,651,000 | – | 88,816 | +100.0% | 6.71% | – |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $24,901,000 | +66.8% | 667,417 | +33.7% | 4.96% | +25.8% |
| ARVN | Buy | ARVINAS INC | $21,778,000 | -34.1% | 517,406 | +5.3% | 4.34% | -50.3% |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $17,594,000 | – | 1,048,516 | +100.0% | 3.51% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $16,857,000 | +38.3% | 876,156 | +24.9% | 3.36% | +4.3% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $15,117,000 | -34.9% | 1,306,569 | +4.0% | 3.01% | -50.9% |
| MRUS | Buy | MERUS N V | $10,239,000 | +55.1% | 452,244 | +81.1% | 2.04% | +17.0% |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $8,955,000 | +66.8% | 1,408,050 | +21.7% | 1.79% | +25.8% |
| TGTX | New | TG THERAPEUTICS INC | $8,350,000 | – | 1,964,709 | +100.0% | 1.66% | – |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $7,036,000 | +133.3% | 826,779 | +145.9% | 1.40% | +75.8% |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $7,006,000 | – | 148,216 | +100.0% | 1.40% | – |
| VOR | Buy | VOR BIOPHARMA INC | $6,482,000 | +20.0% | 1,304,300 | +45.8% | 1.29% | -9.5% |
| OYST | Buy | OYSTER PT PHARMA INC | $5,773,000 | -49.8% | 1,333,330 | +35.0% | 1.15% | -62.1% |
| GRCL | GRACELL BIOTECHNOLOGIES INCsponsored ads | $4,309,000 | +136.1% | 783,445 | 0.0% | 0.86% | +77.8% | |
| LQDA | New | LIQUIDIA CORPORATION | $3,710,000 | – | 850,961 | +100.0% | 0.74% | – |
| CCCC | Sell | C4 THERAPEUTICS INC | $552,000 | -95.4% | 73,149 | -85.4% | 0.11% | -96.6% |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -212,961 | -100.0% | -1.33% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -227,034 | -100.0% | -2.54% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -267,946 | -100.0% | -2.59% | – |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -287,577 | -100.0% | -3.51% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -136,243 | -100.0% | -3.79% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -907,428 | -100.0% | -4.00% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -910,416 | -100.0% | -4.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.